Panacea Biotec Ltd

Panacea Biotec Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Panacea Biotec Ltd

₹ 413 -0.07%
29 May - close price
panaceabiotec.com BSE: 531349 NSE: PANACEABIO
About

Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company[1]

Key Points

Business Overview:[1]
a) PBL is in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food & nutrition products
b) It is one of the largest Vaccine Manufacturing Company in India and is acknowledged by the United Nations (UN) Health Agencies in partnering the Global Polio Eradication Initiative (GPEI) with supplies of billions of doses of WHO Pre-qualified Polio vaccines in 50+ countries worldwide as a sequel to the completion of full range of Oral polio vaccines (tOPV, mOPV1, mOPV3 & bOPV (Type1&Type3)
c) It is the first company to have developed fully liquid Pentavalent vaccine (DTwP-Hep B+Hib) EasyFive and world’s first fully-liquid wP-IPV based Hexavalent vaccine (DTwP +HepB +Hib +IPV) EasySix

Website BSE NSE
  • Market Cap ₹ 2,527 Cr.
  • Current Price ₹ 413
  • High / Low ₹ 534 / 292
  • Stock P/E
  • Book Value ₹ 47.6
  • Dividend Yield 0.00 %
  • ROCE -2.14 %
  • ROE -4.76 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Stock is trading at 8.68 times its book value
  • Company has low interest coverage ratio.
  • Company has a low return on equity of -10.3% over last 3 years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
71.97 75.02 89.41 94.59 95.23 80.37 56.88 76.64 108.43 67.90 112.25 90.81 99.31
59.68 71.59 82.60 84.63 88.59 89.61 67.37 69.90 93.04 86.47 115.27 104.51 100.69
Operating Profit 12.29 3.43 6.81 9.96 6.64 -9.24 -10.49 6.74 15.39 -18.57 -3.02 -13.70 -1.38
OPM % 17.08% 4.57% 7.62% 10.53% 6.97% -11.50% -18.44% 8.79% 14.19% -27.35% -2.69% -15.09% -1.39%
9.71 10.27 3.34 2.13 3.05 16.39 3.80 3.41 3.32 6.09 4.95 3.61 3.84
Interest 2.68 2.70 3.46 3.55 3.41 3.36 3.21 3.76 3.85 4.64 6.00 5.93 7.04
Depreciation 6.08 5.90 5.40 5.34 5.21 5.14 5.08 5.09 5.21 4.91 4.77 4.91 4.89
Profit before tax 13.24 5.10 1.29 3.20 1.07 -1.35 -14.98 1.30 9.65 -22.03 -8.84 -20.93 -9.47
Tax % 0.00% 486.08% 0.00% 0.00% 59.81% 1.48% -8.01% 0.77% 0.00% -43.76% -24.21% -25.27% -22.28%
13.24 -19.69 1.29 3.20 0.43 -1.37 -13.78 1.29 9.65 -12.39 -6.70 -15.64 -7.36
EPS in Rs 2.16 -3.21 0.21 0.52 0.07 -0.22 -2.25 0.21 1.57 -2.02 -1.09 -2.55 -1.20
Raw PDF
Upcoming result date: tomorrow

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
498 679 647 530 184 96 158 344 236 257 360 310 370
586 612 534 460 192 243 248 343 308 320 345 317 407
Operating Profit -88 68 113 70 -8 -147 -90 0 -73 -63 14 -7 -37
OPM % -18% 10% 17% 13% -4% -152% -57% 0% -31% -24% 4% -2% -10%
304 28 75 16 84 322 -14 21 13 34 25 17 18
Interest 148 93 115 104 103 105 5 8 7 10 14 15 24
Depreciation 69 66 71 66 34 33 27 27 26 24 21 20 19
Profit before tax -0 -63 1 -84 -61 37 -136 -13 -94 -63 4 -26 -61
Tax % 0% 3% 38% -14% 17% 29% 13% 12% 0% 40% 16% -42%
-0 -65 1 -73 -72 27 -153 -14 -94 -88 4 -15 -42
EPS in Rs -0.07 -10.64 0.14 -11.85 -11.73 4.33 -24.97 -2.36 -15.27 -14.28 0.58 -2.48 -6.86
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -8%
5 Years: 14%
3 Years: 10%
TTM: 15%
Compounded Profit Growth
10 Years: 6%
5 Years: 13%
3 Years: 22%
TTM: -900%
Stock Price CAGR
10 Years: 16%
5 Years: -1%
3 Years: 51%
1 Year: -21%
Return on Equity
10 Years: -16%
5 Years: -10%
3 Years: -10%
Last Year: -5%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 6 6 6 6 6 6 6 6 6 6 6 6 6
Reserves 556 517 518 450 382 412 887 502 409 320 323 308 286
990 1,031 1,035 1,023 970 689 67 65 84 102 125 228 280
334 325 248 303 316 335 179 217 263 296 300 327 280
Total Liabilities 1,886 1,879 1,807 1,782 1,673 1,442 1,138 790 762 724 754 869 851
1,086 1,060 988 942 891 496 499 464 454 435 423 416 446
CWIP 26 17 19 28 37 3 4 13 1 28 97 119 97
Investments 394 395 395 345 345 3 3 0 0 0 0 0 0
380 408 406 467 401 940 633 313 307 260 234 334 309
Total Assets 1,886 1,879 1,807 1,782 1,673 1,442 1,138 790 762 724 754 869 851

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
53 45 98 104 172 107 -83 38 -53 -11 33 4
-18 -29 23 -18 -3 -10 -17 -37 40 2 -47 -61
-38 -11 -129 -91 -164 -98 109 -7 10 9 13 90
Net Cash Flow -3 5 -8 -5 6 -2 10 -6 -3 1 -1 33
Free Cash Flow 37 41 97 80 157 102 -69 28 -59 -10 -36 -49
CFO/OP -62% 71% 69% 140% -2,130% -73% 83% 8,010% 71% 15% 247% -73%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 66 54 80 121 283 96 41 37 36 17 11 25
Inventory Days 310 178 233 304 618 203 619 180 421 260 278 541
Days Payable 397 236 295 490 1,002 373 847 257 472 289 299 586
Cash Conversion Cycle -20 -4 17 -65 -102 -74 -188 -39 -15 -12 -10 -21
Working Capital Days -403 -229 -80 -133 -682 -49 892 4 -63 -135 -79 -141
ROCE % -9% 2% 4% 4% 3% -14% -8% -1% -16% -13% 4% -2%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Number of Active Patents (Global)
Number

Log in to view insights

Please log in to see hidden values.

Login
Number of R&D Scientists
Number
Distribution Network - Vaccine Distributors
Number
Field Force Size (Sales & Marketing Staff)
Number
Distribution Network - Pharma Distributors
Number
Market Share - Tacrolimus (PanGraf)
%
Market Share - Transplant & Immunology Segment
%
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
73.59% 73.59% 73.59% 73.59% 73.47% 72.87% 72.49% 72.48% 72.48% 72.48% 72.48% 72.48%
0.22% 0.26% 0.26% 0.27% 0.26% 0.37% 0.38% 1.16% 0.79% 1.06% 1.36% 1.60%
0.54% 0.57% 0.69% 0.84% 1.07% 1.16% 1.16% 1.49% 1.52% 1.80% 1.85% 1.96%
25.66% 25.58% 25.46% 25.30% 25.21% 25.60% 25.96% 24.86% 25.20% 24.65% 24.31% 23.96%
No. of Shareholders 47,81548,87847,09146,24245,51339,98235,44633,59334,25633,59334,59732,620

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Aug 2021
    Transcript
    AI Summary
    PPT
  • Jul 2021
    Transcript
    AI Summary
    PPT